Myrobalan Therapeutics Completes Series A Financing of $24 Million to Develop Potentially First-in-Class CNS Therapeutics with Restorative Potential
Retrieved on:
Wednesday, January 10, 2024
Health, Neurology, Research, Pharmaceutical, Science, Biotechnology, Constellation, Patient, Therapy, Biology, Remyelination, Drug design, ALS, Broad Institute, Multiple sclerosis, Partnership, Harvard Medical School, National academy, GPR17, Venture, Neuroinflammation, MIT, Sympathetic nervous system, Drug development, TYK2, Traffic barrier, Harvard University, Capital, Limited partnership, CNS, Pharmaceutical industry
Myrobalan has the potential to overcome such obstacles with the development of highly selective, brain-penetrant, orally available compounds against promising novel targets involved in demyelination and neuroinflammation.
Key Points:
- Myrobalan has the potential to overcome such obstacles with the development of highly selective, brain-penetrant, orally available compounds against promising novel targets involved in demyelination and neuroinflammation.
- These currently untreatable disease mechanisms have been linked to multiple sclerosis (MS), Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and several rare neurological conditions.
- “Our deep understanding of remyelination and neuroinflammation has broad application in high-unmet need CNS diseases,” said Dr. Jing Wang, CEO & Co-Founder, Myrobalan Therapeutics.
- Myrobalan Therapeutics' unique strategy holds great promise in overcoming challenges associated with central nervous system diseases.